Defence Therapeutics Inc (OP:DTCFF)

0.5461 -0.0298 (-5.17%)

Streaming Delayed Price Updated: 3:13 PM EST, Dec 30, 2025 Add to My Watchlist

Price and Volume

Volume	11,578
Open	0.5135
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.5759
Today's Range	0.4989 - 0.5648
52wk Range	0.3901 - 1.157
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th

December 11, 2025

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

From Virtual Investor Conferences; Defence Therapeutics

Via GlobeNewswire

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

December 09, 2025

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Performance

YTD	+21.4%	+21.4%
1 Month	-4.7%	-4.7%
3 Month	+7.7%	+7.7%
6 Month	+5.7%	+5.7%
1 Year	+40.0%	+40.0%

More News

Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

November 14, 2023

Via PressReach

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

Via FinancialNewsMedia

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

November 07, 2023

Via PressReach

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

Via FinancialNewsMedia

Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer

October 18, 2023

Via PressReach

Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

October 17, 2023

Via PressReach

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

October 10, 2023

Via PressReach

Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science

October 10, 2023

Via PressReach

Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines

September 26, 2023

Via PressReach

BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment

May 10, 2023

Via Newsfile

BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News

May 04, 2023

Via Newsfile

Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market

September 29, 2022

Via Newsfile

Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

September 21, 2022

Via Newsfile

Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative

September 16, 2022

Via Newsfile

Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)

October 19, 2021

Via AB Newswire

Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)

October 12, 2021

Via AB Newswire

Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)

October 05, 2021

Via AB Newswire

Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)

September 28, 2021

Via AB Newswire

Frequently Asked Questions

Is Defence Therapeutics Inc publicly traded?

Yes, Defence Therapeutics Inc is publicly traded.

What exchange does Defence Therapeutics Inc trade on?

Defence Therapeutics Inc trades on the OTC Traded

What is the ticker symbol for Defence Therapeutics Inc?

The ticker symbol for Defence Therapeutics Inc is DTCFF on the OTC Traded

What is the current price of Defence Therapeutics Inc?

The current price of Defence Therapeutics Inc is 0.5461

When was Defence Therapeutics Inc last traded?

The last trade of Defence Therapeutics Inc was at 12/30/25 03:13 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.